|
PTIX | Protagenic Therapeutics, Inc.new |
|
|
PTIX | Protagenic Therapeutics, Inc.new |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -3.23 |
| Leverage | 154.00% |
| Market Cap | $ 740.7k |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -1.7m |
| Margin | -48.17% |
Protagenic Therapeutics, Inc., a preclinical biopharmaceutical company, is dedicated to the discovery and development of therapies to treat stress-related mood and neuropsychiatric disorders. The company is headquartered in New York, New York.